Glycos Biomedical Private Limited - Company Profile

It is a pharma foreign private limited company based in Hyderabad, Telangana, India, established in 2021.
2021 Hyderabad, Telangana, India Active
Last Updated:
Access Report
About Glycos Biomedical Private Limited

Glycos Biomedical Private Limited, a active foreign private limited company, was established on 03 September 2021 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24230TG2021FTC154601. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.

Its leadership includes Pervinder Singh Bhogal (Director), Santosh Kumar Manupati (Director), Ounali Sherali Jaffer (Director). It is based at H No-5-11/112/212 Senthan Green Park Near Teachers Colony, Hyderabad, Telangana, 502032.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24230TG2021FTC154601

  • Registration Number

    154601

  • Incorporation Date

    03 September 2021

  • Authorized Capital

    ₹1.00 M

  • Paid-Up Capital

    ₹0.10 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 1.00 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 4 Year, 6 Months
Company report

Glycos Biomedical Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Glycos Biomedical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Glycos Biomedical Private Limited?
Current Directors
Name Designation Appointment Date Status
Pervinder Singh Bhogal Director 03 Sep 2021 Current
Santosh Kumar Manupati Director 03 Sep 2021 Current
Ounali Sherali Jaffer Director 03 Sep 2021 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Glycos Biomedical.

Enhance accessibility to Glycos Biomedical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Glycos Biomedical revenue growth over time
Glycos Biomedical profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Glycos Biomedical?

Unlock access to Glycos Biomedical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Glycos Biomedical?

Glycos Biomedical has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Glycos Biomedical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glycos Biomedical's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Glycos Biomedical
Recent Activity within the Organization
  • Director Appointment

    Progress on Pervinder Singh Bhogal was appointed as a Director was appointed as a Director on 03 Sep 2021 & has been associated with this company since 4 years 6 months . was documented.

  • Director Appointment

    The activity Santosh Kumar Manupati was appointed as a Director was appointed as a Director on 03 Sep 2021 & has been associated with this company since 4 years 6 months . was completed.

  • Director Appointment

    Progress on Ounali Sherali Jaffer was appointed as a Director was appointed as a Director on 03 Sep 2021 & has been associated with this company since 4 years 6 months . was documented.

  • Company Incorporation

    Progress on Glycos Biomedical Private Limited was registered on 03 Sep 2021 with Roc Hyderabad & aged 4 years 6 months as per MCA records. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Glycos Biomedical Private Limited?

The CIN of Glycos Biomedical Private Limited is U24230TG2021FTC154601.

Where is Glycos Biomedical Private Limited headquartered?

Glycos Biomedical Private Limited is headquartered at H No-5-11/112/212 Senthan Green Park Near Teachers Colony, Hyderabad, Telangana, 502032.

When was Glycos Biomedical Private Limited incorporated?

Glycos Biomedical Private Limited was incorporated on 03 September 2021.

Who are the current directors of Glycos Biomedical Private Limited?

The current directors of Glycos Biomedical Private Limited are

What is the primary industry of Glycos Biomedical Private Limited?

The primary industry of Glycos Biomedical Private Limited is Pharma.

Is Glycos Biomedical Private Limited a listed company?

Glycos Biomedical Private Limited is unlisted.

What is the capital structure of Glycos Biomedical Private Limited?

The authorized capital of Glycos Biomedical Private Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available